Vitiligo therapy: restoring immune privilege?
- PMID: 27314920
- DOI: 10.1111/exd.13128
Vitiligo therapy: restoring immune privilege?
Abstract
The therapeutic hypothesis proposed by Speeckaert and van Geel in this issue (1) is based on the dramatic effects of the new drugs targeting immune privilege checkpoints (PD1/PDL, CTLA4) in current advanced melanoma therapy as major inductors of vitiligo changes in the skin. Such striking clinical manifestations cannot be classified as mere side effects without considering possible consequences for spontaneously occurring vitiligo."
Keywords: immune privilege; melanoma; vitiligo.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Comment on
-
Targeting CTLA-4, PD-L1 and IDO to modulate immune responses in vitiligo.Exp Dermatol. 2017 Jul;26(7):630-634. doi: 10.1111/exd.13069. Epub 2016 Oct 3. Exp Dermatol. 2017. PMID: 27192950
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
